Abstract: [Problem to be Solved] Provided is a delivery carrier into the cell having high antioxidant activity, intracellular absorbability, intracellular disintegration property, stability and safety, which have high delivery property of the active ingredient to cell and living tissues. [Solution] The delivery carrier into cells includes a vitamin derivative with co-activation of both autophagy-related genes and protease synthesis genes, a polymer molecule containing stimulatory reactivity, an emulsion stabilizer, an active ingredient, and a lipid, thereby providing a delivery carrier into cells with high delivery properties of the active ingredient to cells and living tissues.

Abstract: An edible enterosorbent containing a treated enterosorbent, wherein the treated enterosorbent comprises a parent sorbent that has been acid and/or lecithin treated, and wherein the treated sorbent is operable for adsorption of one or more toxins from a gastrointestinal tract of a living being when introduced thereto, such that a bioavailability of and exposure of the living being to the one or more toxins is decreased. Methods of making and utilizing the edible enterosorbent are also provided.

Abstract: A film and a method for use thereof such as for the administration of a biologically active agent or for therapy are provided. Specifically, a film, composed of a biodegradable material having a mucoadhesive surface comprising a plurality of mushroom-type structures is provided.

Abstract: Described are oral, liquid pharmaceutical compositions that include sodium picosulfate, magnesium oxide, citric acid, and malic acid, and methods of making and using such compositions.

Abstract: The present disclosure relates to a continuous process for impregnating active pharmaceutical ingredients (API) onto porous carriers, including the steps of introducing a porous carrier into a first feeder; continuously directing the porous carrier from the first feeder into a continuous blender, wherein the continuous blender comprises one or more nozzles; continuously introducing a solution comprising an API dissolved in solvent into the continuous blender through the one or more nozzles to form API-impregnated porous carrier; and continuously drying the API-impregnated porous carrier using a fluidized bed dryer to form a powder. The present disclosure also relates to a continuous process for manufacturing pharmaceutical drug products using continuously manufactured API-impregnated porous carriers. The present disclosure also relates to a continuous pharmaceutical drug manufacturing process that includes API-impregnated porous carriers as a raw material.

Abstract: Ready to use semi-naked dilute solutions of phenylephrine, resistant to oxidative degradation when packaged in transparent or translucent collapsible polypropylene bags and terminally sterilized, without the need for an aluminum over-wrap, oxygen scavengers, oxygen impermeable polypropylene, antioxidants, or chelating agents.

Abstract: The present invention relates to a porous structure-based magnetically actuated microrobot and a fabricating method therefor, wherein the porous structure-based magnetically actuated microrobot is based on a natural polymer having biocompatibility and biodegradability, so that the precise targeting of the porous microrobot through the attachment of magnetic nanoparticles and the drug and cell delivery using the porous microrobot can be attained.

Abstract: A cellulose composition containing cellulose, glucose and sorbitol, wherein a total content of glucose and sorbitol is 0.7 mg or more and 4.0 mg or less per 5 g of the cellulose composition. A tablet contains the cellulose composition. An orally disintegrating tablet contains the cellulose composition.

Abstract: The invention relates to a solid cosmetic composition comprising aqueous spheroids dispersed in a solid anhydrous continuous phase. The invention is also directed toward a process for preparing a solid cosmetic composition according to the invention, and also a process for making up and/or caring for bodily and/or facial skin using a solid cosmetic composition according to the invention. The invention is also directed toward a stick or a solid gel cast in a dish or a pot, and more particularly a lipstick, a foundation, and an antisun stick, comprising a cosmetic composition according to the invention.

Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

Abstract: An object of the present invention is to provide a powder preparation and the like suitable for selective administration to an olfactory region and the like. The object is achieved by a powder preparation for selectively administering an active ingredient to an olfactory region in a nasal cavity, the powder preparation comprising the active ingredient and having a bulk density of 0.1 to 0.5 g/cm3 and a Hausner ratio of 1.6 to 2.4.

Abstract: Disclosed are a liquid supramolecular self-recognition system of low-pH azelaic acid, and a preparation method therefor and application thereof. The preparation method for the ternary liquid supramolecular self-recognition system of low-pH azelaic acid/succinic acid/panthenol includes the following steps: mixing and heating azelaic acid, succinic acid, and panthenol in a molar ratio of 1:0.5:1-1:10:10 in a sealed container to obtain a mixture and heated at 60-120° C. for more than 1-24 hours, and cooling down the mixture to room temperature after the heating is completed to obtain the liquid supramolecular self-recognition system of low-pH azelaic acid. The preparation method is green and simple, and the resulting supramolecular self-recognition system can effectively improve the solubility of azelaic acid, and have excellent stability without precipitation.

Abstract: This invention relates to improving delivery of agents to the central nervous system.

Abstract: The present disclosure provides wound dressing compositions that disrupt biofilm formation in a wound upon application. The wound dressing composition includes a first layer comprising a homogeneous mixture of a collagen, an oxidized regenerated cellulose (ORC), and at least one bacteria reducing active ingredient and a second layer comprising a homogeneous mixture of a collagen, an oxidized regenerated cellulose (ORC), a silver compound, and at least one bacteria reducing active ingredient, and the uses thereof. Also disclosed herein are kits comprising the wound dressing compositions of the present technology, and instructions for use.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one liposome and an antipsychotic drug with a high drug to lipid ratio and encapsulation efficiency. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the antipsychotic drug. Also provided is the method for treating schizophrenia or bipolar disorder using the pharmaceutical composition disclosed herein.

Abstract: Disclosed herein are compositions comprising (a) a pyridine carboxylate herbicide or an agriculturally acceptable N-oxide, salt, or ester thereof and (b) an acetolactate synthase (ALS) inhibitor or an agriculturally acceptable salt or ester thereof. Also disclosed herein are methods of controlling undesirable vegetation, comprising applying to vegetation or an area adjacent the vegetation or applying in soil or water to control the emergence or growth of vegetation (a) a pyridine carboxylate herbicide or an agriculturally acceptable N-oxide, salt, or ester thereof and (b) an ALS inhibitor or an agriculturally acceptable salt or ester thereof.

Abstract: This invention relates to stabilizer concentrates which improve the stability of mono- and/or diesters of mono- and/or diethylene glycol wax dispersions in personal care compositions, wherein the stabilizer concentrates comprising hydrogenated castor oil and betaines and are free of anionic surfactants.

Abstract: The present invention relates to filamentous, i.e. thread-like nanoparticles comprising sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin. More particularly, the invention relates to the use of said thread-like nanoparticles in vaccines and drug delivery or adsorption systems systems, methods for their production and uses thereof, such as for use as a vaccine adjuvant and in cancer therapy.

Abstract: Technical field The invention relates to new calibrated-size gas-filled microvesicles bearing an overall positive charge, to their use and to their method of manufacturing. The gas-filled microvesicles have a geometric standard deviation (GSD) value of at least 1.25 or lower and a stabilizing envelope comprising an amphiphilic material, said amphiphilic material comprising a cationic lipid and a neutral or cationic amphiphilic polymeric compound.

Abstract: A liposome composition comprising a lipophilic prodrug of mitomycin C having an improved pharmacokinetic profile is described. A method for preparing the composition with a solvent system comprised of ethanol and tertiary butanol mixed at an adequate ratio is also described. In an embodiment, the liposome composition is a population of lipid nanoparticles and a pharmaceutically acceptable vehicle, wherein the population of lipid nanoparticles is comprised of a first fraction of spherical liposomes and a second fraction of rod-shaped lipid nanoparticles, where the second fraction is less than about 15% of the population of lipid nanoparticles.